Boehringer Ingelheim announced that the National Medical Products Administration (NMPA) of China has approved HERNEXEOS® (zongertinib tablets) as a monotherapy treatment for adult patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors harbor activating HER2 (ERBB2) mutations and who have already received at least one prior systemic therapy.
The accelerated approval follows a Breakthrough Therapy Designation and Priority Review, reflecting the significant clinical benefit observed. A leading oncologist noted a critical unmet need for a well-tolerated, oral HER2-targeting drug in NSCLC, emphasizing that zongertinib‘s approval addresses this gap. The expert also highlighted the drug’s potential to improve outcomes for patients with a poor prognosis and limited treatment choices.
The conditional approval is based on data from the Phase Ib Beamion-LUNG 1 trial. This trial demonstrated a 71% objective response rate in 75 participants. Results showed a high disease control rate, with a median duration of response of 14.1 months and a median progression-free survival of 12.4 months. These findings were previously presented at the American Association for Cancer Research (AACR) Annual Meeting and published in The New England Journal of Medicine. HERNEXEOS® also showed a manageable safety profile with a low discontinuation rate.
Further highlighting the drug’s promise, zongertinib recently received Breakthrough Therapy Designation from China‘s Center for Drug Evaluation (CDE) for first-line treatment of adult patients with unresectable or metastatic NSCLC with activating HER2 mutations. A Boehringer Ingelheim executive expressed optimism about the NMPA‘s recognition of zongertinib‘s potential and the urgent need for this therapy. The executive also indicated plans to explore zongertinib‘s use in other cancers, such as breast cancer, and in a tumor-agnostic setting.
Lung cancer is a leading cause of cancer death in China, with increasing incidence and mortality rates. NSCLC accounts for the majority of lung cancer cases, and HER2 mutations, though relatively uncommon, are associated with a poor prognosis. These mutations drive uncontrolled cell growth, contributing to tumor development and spread.
Zongertinib, an irreversible tyrosine kinase inhibitor, selectively targets HER2 while sparing wild-type EGFR, minimizing potential toxicities. It is administered orally and has also received Orphan Drug Designation in Japan. Boehringer Ingelheim is actively pursuing further research to assess the potential of zongertinib across a broader range of cancers. The company has initiated clinical studies to evaluate this therapy in other cancers and settings.
Related
